Director, HEOR Therapeutic Area Lead; Acromegaly

Position Summary

Crinetics is a pharmaceutical company based in San Diego, California, developing much-needed therapies for people with endocrine diseases and endocrine‑related tumors. The Director, HEOR/RWE Therapeutic Area (TA) Lead – Paltusotine (Acromegaly) is the stakeholder‑facing HEOR/RWE owner for the acromegaly franchise. As Crinetics’ lead product, PALSONIFY (paltusotine), moves through launch and lifecycle management in acromegaly, this role defines the therapeutic‑area evidence strategy – the value story, evidence gaps, and HEOR/RWE priorities – and partners with Medical Affairs, Market Access, Commercial, Clinical Development, and Patient Advocacy to anchor that evidence to launch, access, and lifecycle decisions.

The TA Lead does not execute studies directly; working with the Senior Director, Paltusotine Program, the Director translates acromegaly evidence questions into prioritized plans and directs the HEOR/RWE Centers of Excellence (RWE, PRO/COA, Modeling & Simulation, Advanced Analytics) to deliver them.

• Own the acromegaly HEOR/RWE evidence strategy across the product lifecycle – define the value narrative, identify evidence gaps, and set TA‑level evidence priorities for PALSONIFY (paltusotine).
• Serve as the primary HEOR/RWE point of contact for acromegaly franchise stakeholders – Medical Affairs, Market Access, Commercial, Clinical Development, Patient Advocacy, and regional/affiliate teams.
• Translate franchise evidence questions into prioritized, executable plans and commission delivery through the HEOR/RWE Centers of Excellence (RWE, PRO/COA, Modeling & Simulation, Advanced Analytics).
• Contribute the acromegaly HEOR/RWE narrative to integrated evidence plans, value dossiers, AMCP and global value dossiers, and HTA submissions.
• Partner with Market Access on payer value propositions, budget impact, and access strategy for acromegaly.
• Align acromegaly evidence generation to launch, access, and lifecycle milestones; anticipate evidence needs ahead of PhaseIII and regulatory windows.
• Represent the acromegaly evidence story to KOLs, payers, HTA bodies, and at scientific congresses.
• Support the Senior Director, Paltusotine Program in maintaining a coherent franchise value story, coordinating with the carcinoid syndrome lead across indications.
• Monitor the competitive and treatment landscape in acromegaly and translate implications into evidence strategy.
• Ensure compliance with corporate policies and US healthcare laws governing evidence generation and communication.
• Other duties as assigned.

• Advanced degree in health economics, outcomes research, epidemiology, health services research, public health, or related discipline (PhD, MD, PharmD, MPH, MSc).
• Minimum of 10+ years of relevant pharmaceutical, biotech, or HEOR consulting experience.
• Minimum of 8+ years of supervisory experience.
• Demonstrated ability to define and drive a therapeutic‑area evidence strategy across the product lifecycle (pre‑launch through lifecycle management).
• Strong stakeholder management and influencing skills, with a track record of partnering with Medical Affairs, Market Access, and Commercial.
• Working knowledge across the HEOR/RWE toolkit – RWE, PRO/COA, economic modeling, and HTA evidence requirements – sufficient to commission and quality‑check work delivered by Centers of Excellence.
• Experience contributing HEOR evidence to value dossiers and HTA/payer submissions.
• Excellent communication and interpersonal skills, with the ability to influence senior business leaders across functions and geographies.
• Ability to lead, collaborate, and influence cross‑functional teams.
• Ability to ensure compliance with corporate policies and procedures, as well as US healthcare laws and regulations.
• Flexible, adaptable, and able to operate effectively in ambiguity within a fast‑scaling pipeline.

• Experience in rare or specialty endocrine, or other niche‑population therapeutic areas.
• Acromegaly, neuroendocrine, or related specialty experience.
• Familiarity with launch and lifecycle HEOR for a recently launched product.